Evercore ISI initiated coverage of Evommune (EVMN) with an Outperform rating and $40 price target The Immunology and Inflammation focused company’s portfolio of assets has lead indications in chronic itching/hives and eczema and it is pursuing novel targets, so they are inherently higher risk/reward, but “these types of positive readouts are exactly what the public markets have been rewarding,” the analyst tells investors. Evommune has three important binary readouts in 2026, so this is “set to be a huge year for the company,” the analyst added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune initiated with an Outperform at William Blair
- Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential
- Evommune initiated with an Overweight at Morgan Stanley
- Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership
- Opening Day: DNA test maker BillionToOne raises $314M in IPO